Search - tctmd.com

Displaying 861 - 880 of 1590

Sort: Relevancy | Date

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

News Daily News

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

Michael O'Riordan

April 29, 2020

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

ACE Inhibitors/ARBs Safe, Possibly Protective in Hypertensive COVID-19 Patients

News Daily News

ACE Inhibitors/ARBs Safe, Possibly Protective in Hypertensive COVID-19 Patients

April 24, 2020

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

COVID-19 Drug Candidates May Raise Arrhythmia Risk

News Daily News

COVID-19 Drug Candidates May Raise Arrhythmia Risk

April 03, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice

News Daily News

ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice

Yael L. Maxwell

March 26, 2020

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

News Daily News

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

March 25, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Inclisiran Data in NEJM Prompt Talk of What Comes Next

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

March 24, 2020

Missed Opportunities: Many HF Patients Not Tested for CAD

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

March 20, 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

News Conference News ACC 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

Yael L. Maxwell

March 19, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.